Rapid Micro Biosystems Q2 2026 Earnings: Gross Margin Reaches 15%

Rapid Micro Biosystems (Nasdaq: RPID) reported Q2 2026 revenue of $8.1 million, up 10.9% from $7.3 million, while diluted net loss per share was $0.27, unchanged year over year. Gross margin reached a record second-quarter 15.0%, and recurring revenue grew 14.3% to represent 63% of total revenue. However, higher operating expenses and interest costs kept the company’s losses elevated.

Core financial results

Revenue increased by $792,000, while total cost of revenue decreased by $145,000. That combination lifted gross profit by $937,000 and expanded gross margin by 11.2 percentage points from the prior-year quarter.

The improvement did not extend to the bottom line. Operating expenses increased 8.9%, the adjusted EBITDA loss widened slightly, and net loss increased by approximately $1.1 million.

Business and operating performance

Product revenue increased 10.1% to $5.3 million, while service revenue rose 12.5% to $2.8 million. Recurring revenue grew faster than total revenue, increasing 14.3% to $5.0 million. Consumables revenue increased by more than 20% and reached a quarterly record, although the company did not disclose the exact amount.

Rapid Micro placed four Growth Direct systems, unchanged from Q2 2025. System validations increased to nine from two, indicating that more previously placed systems moved through the customer validation process. The company also reached 200 cumulative Growth Direct systems placed globally.

Gross margin gains were absorbed by operating costs and interest expense

The gross margin expansion was supported by revenue growth alongside lower total cost of revenue. Service cost of revenue declined to $1.4 million from $1.7 million even as service revenue increased, while product cost rose only slightly to $5.4 million as product revenue grew 10.1%.

Operating expenses nevertheless increased by approximately $1.1 million, exceeding the $937,000 increase in gross profit. General and administrative expenses rose 11.3%, sales and marketing expenses increased 10.3%, and research and development expenses grew 3.2%. As a result, the operating loss remained above $12 million.

Below the operating line, total other income and expense shifted from $301,000 of income to $556,000 of expense. Interest expense increased to $646,000 from $12,000, while interest income declined to $140,000 from $351,000. This change helps explain why the net loss widened more than the operating loss.

Liquidity and balance sheet

Cash and cash equivalents totaled $14.7 million at June 30, 2026, and short-term investments were $5.1 million, giving the company approximately $19.8 million of cash and short-term investments. That was down from approximately $38.3 million at December 31, 2025.

Notes payable were $19.1 million, compared with $18.9 million at year-end. Inventory increased to $18.9 million from $17.6 million, while accounts receivable rose to $5.5 million from $3.1 million. The decline in liquid assets remains important because the company continues to report substantial net and adjusted EBITDA losses.

2026 guidance

Rapid Micro reaffirmed its full-year revenue, system placement, and gross margin forecasts while increasing its system validation target. The validation change is consistent with the increase to nine completed validations during Q2.

First-half revenue was $16.1 million, meaning the company would need approximately $20.9 million to $24.9 million of second-half revenue to reach its full-year range. First-half gross margin was approximately 9.9%, while management expects second-half gross margin in the mid-20% range. Achieving that margin step-up is therefore central to the full-year outlook.

Management’s view

CEO Robert Spignesi attributed the quarter’s progress to execution against the company’s strategic and margin-expansion priorities. Management highlighted customer engagement, multi-system and enterprise deployment opportunities, and an expanding contribution from the MilliporeSigma collaboration as potential second-half drivers.

The company also cited increased adoption of automation, U.S. reshoring, and expansion in biomanufacturing capacity as supportive industry trends. These comments represent management’s outlook rather than reported financial results.

Recent insider transactions

Yahoo Finance’s six-month summary listed 601,187 shares purchased across 16 insider transactions and 119,466 shares sold across nine transactions, resulting in 481,721 net shares purchased. The latest ten reported entries, however, consisted primarily of stock awards and exercise-related conversions rather than clearly identified open-market purchases.

These reported transactions do not by themselves establish insiders’ views about the company’s prospects.

Risks investors should monitor

• Continued losses: The $12.9 million quarterly net loss exceeded revenue, and adjusted EBITDA remained negative at $10.3 million despite the gross margin improvement.
• Reduced liquidity: Cash and short-term investments declined by approximately $18.5 million during the first half, while notes payable remained above $19 million.
• Second-half execution requirements: Reaching the annual revenue range requires second-half revenue above the first-half level, along with gross margin rising into the mid-20% range.
• Expense and financing pressure: Higher operating expenses and interest costs could continue to offset additional gross profit gains.
• System placement execution: Q2 placements were unchanged at four, while the full-year plan continues to call for 30 to 38 placements.

Summary

Rapid Micro’s Q2 2026 results showed meaningful gross margin improvement and faster growth in recurring and consumables revenue, supported by a larger number of system validations. Those gains have not yet reduced operating or net losses because expenses and interest costs remain high. The main items to monitor are the expected second-half margin increase, execution against the full-year placement and revenue targets, and the company’s remaining liquidity.